At present, Mexico has a sound regulation for biocomparables or biosimilars. Notwithstanding, as in other countries, the regulation for biosimilar orphan medicines remains a grey area, as there is no clear path for their development and evaluation. This situation has allowed the commercialization of non - innovator orphan medicines that do not meet biocomparability criteria, with the consequent risk for patients. This was the case of Asbroder®, an intended copy of imiglucerase that was marketed in Mexico in 2015 but then withdrawn in 2020. This article discusses the limitations in the regulation of biosimilar orphan medicines and the pharmacovigilance activities required to ensure patient safety, emphasizing replacement therapies with recombinant enzymes. Our purpose is to provide elements of discussion allowing the generation of adequate regulation for biosimilar orphan medicines. Health authorities are advised to consider these aspects to create regulations ensuring biosimilar orphan drugs' quality, efficacy, and safety.